News & Media

Recent updates from Arcutis.

January 13, 2020

Arcutis Announces Exercise of Option for Exclusive License to Highly Selective JAK1 Inhibitor for All Topical Dermatological Uses in U.S., Canada, Europe and Japan

January 8, 2020

Arcutis Announces Enrollment of First Patients in Two Pivotal Phase 3 Clinical Trials Evaluating ARQ-151 as a Potential Once Daily Topical Treatment for Plaque Psoriasis

January 6, 2020

Arcutis Biotherapeutics Announces Filing of Registration Statement for Proposed Initial Public Offering

December 16, 2019

Arcutis Announces Top Line Results for Phase 2 Proof-of-Concept Clinical Trial Evaluating ARQ-151 as a Potential Topical Treatment for Atopic Dermatitis

December 5, 2019

Arcutis Announces ARQ-154 Program for Seborrheic Dermatitis and Enrollment of First Patient in Phase 2 Proof of Concept Clinical Trial

November 14, 2019

Arcutis Appoints Keith Klein as General Counsel

October 30, 2019

Arcutis Announces Addition of Three Senior Biopharmaceutical Executives to Management Team

October 24, 2019

Arcutis Biotherapeutics Announces Positive End-of-Phase 2 Meeting with FDA and Planned Initiation of Phase 3 Program for ARQ-151 for Plaque Psoriasis

October 21, 2019

Arcutis Announces the Completion of $94.5 million Series C Financing

October 9, 2019

Arcutis Announces Enrollment of Last Patient in Phase 2a Clinical Trial of ARQ-151 Cream as a Potential Topical Treatment for Atopic Dermatitis

September 18, 2019

Arcutis, Inc.’s Development Program for Eczema

July 22, 2019

Arcutis, Inc. Announces Positive Top Line Results for Phase 2b Clinical Trial Evaluating ARQ-151 as a Potential Topical Treatment for Plaque Psoriasis

Media Resources

Corporate Fact Sheet

Uncovering Psoriasis

Journal of the American Medical Association Roflumilast Cream 0.3% Result

Media Contact

Amanda Sheldon

805.418.5006
media@arcutis.com

Meaningful innovation at a glance.

Download our corporate fact sheet.

Download